AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Fred Tasker
Sep. 12--The diabetes drug Avandia can significantly increase a patient's risk of heart attack, while its biggest competitor, Actos, can decrease the risk of heart attack, stroke and death, according to an analysis in today's Journal of the American Medical Association.
The article says both drugs increase the risk of heart failure -- the inability of the heart to pump blood adequately -- although without increasing the risk of death from heart failure.
These findings raise new questions about the entire class of drugs to which both drugs belong, and create a quandary for doctors over what to prescribe for patients with diabetes.
"It's a tough call," says Dr. Ronald Goldberg, professor of medicine at the University of Miami's…